Premium
Lung Ultrasound Can Influence the Clinical Treatment of Pregnant Women With COVID ‐19
Author(s) -
Yassa Murat,
Birol Pinar,
Mutlu Ali Memis,
Tekin Arzu Bilge,
Sandal Kemal,
Tug Niyazi
Publication year - 2021
Publication title -
journal of ultrasound in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.574
H-Index - 91
eISSN - 1550-9613
pISSN - 0278-4297
DOI - 10.1002/jum.15367
Subject(s) - medicine , asymptomatic , covid-19 , lung , computed tomographic , ultrasound , radiology , computed tomography , disease , infectious disease (medical specialty)
Lung ultrasound (LUS) is an effective tool to detect and monitor patients infected with 2019 coronavirus disease (COVID‐19). The use of LUS on pregnant women is an emerging trend, considering its effectiveness during the outbreak. Eight pregnant women with a diagnosis of COVID‐19 confirmed by nasal/throat real‐time reverse transcription polymerase chain reaction testing who underwent point‐of‐care LUS examinations after routine obstetric ultrasound are described. A routinely performed LUS examination revealed serious lung involvement in 7 cases: 2 were initially asymptomatic; 3 have chest computed tomography; 1 had initial negative real‐time reverse transcription polymerase chain reaction results; and 1 had initial negative computed tomographic findings. Treatment for COVID‐19 was either commenced or changed in 87.5% of the patients (n = 7 of 8) on LUS findings. Among patients with abnormal LUS findings, treatment was commenced in 5 patients (71.5%) and changed in 2 patients (28.5%). One normal and 7 abnormal LUS cases indicate the impact of routine LUS on the clinical outcome and treatment of pregnant women.